

Xavier Garc a Del Muro Solans

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/273237/publications.pdf>

Version: 2024-02-01

15
papers

727
citations

933447

10
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

1267
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490. | 1.6 | 15 |
| 2 | Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103683. | 4.4 | 12 |
| 3 | Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1563-1574. | 1.6 | 108 |
| 4 | Abstract CT040: Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130. <i>Cancer Research</i> , 2021, 81, CT040-CT040. | 0.9 | 8 |
| 5 | Abstract CT042: Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130. <i>Cancer Research</i> , 2021, 81, CT042-CT042. | 0.9 | 10 |
| 6 | Abstract CT187: Overall survival (OS) by response during "induction" from the global, randomized Phase III IMvigor130 study of atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated metastatic urothelial carcinoma (mUC). <i>Cancer Research</i> , 2021, 81, CT187-CT187. | 0.9 | 3 |
| 7 | Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498. | 12.8 | 237 |
| 8 | Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 452-460. | 1.9 | 11 |
| 9 | DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5012-5012. | 1.6 | 48 |
| 10 | Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy as bladder-sparing therapy in patients with localized muscle invasive bladder cancer: A SOGUG study.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5097-TPS5097. | 1.6 | 5 |
| 11 | Optimization of the Therapeutic Approach to Patients with Sarcoma: Delphi Consensus. <i>Sarcoma</i> , 2019, 2019, 1-14. | 1.3 | 4 |
| 12 | Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 134-144. | 10.7 | 97 |
| 13 | Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. <i>Acta Neuropathologica</i> , 2018, 136, 327-337. | 7.7 | 104 |
| 14 | Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients. <i>Oncotarget</i> , 2018, 9, 17576-17588. | 1.8 | 1 |
| 15 | Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA): Tj ETQq1 1 0.784314 rgBT /Overlook 2017, 18, 672-681a. | 10.7 | 49 |